| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | 6.5% | n/a |
| ROCE | 10.2% |
| Latest | F'cast | |
|---|---|---|
| P/E | 29.3 | n/a |
| PEG | 0.9 | n/a |
| Pr/Revenue | 0.7 | n/a |
| Pr/Book | 0.7 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 10.0% | n/a |
| PBT | 30.8% | n/a |
| EPS | 30.9% | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Mar-22 | 82.19 | 1.39 | (1.01)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Mar-23 | 85.31 | 5.10 | 1.49p | 64.8 | n/a | n/a | n/a | 0.0% |
| 31-Mar-24 | 89.42 | 2.97 | 1.55p | 55.2 | 13.8 | +4% | n/a | 0.0% |
| 31-Mar-25 | 79.60 | 4.46 | 2.49p | 21.5 | 0.4 | +61% | n/a | 0.0% |
| 31-Mar-26 | 87.53 | 5.83 | 3.26p | 29.3 | 0.9 | +31% | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| ECOVAXXIN® MS EU marketing authorisation granted | 22-Dec-2025 | 07:00 | RNS |
| Traded | Action | Notifier | Price | Amount | Value |
|---|---|---|---|---|---|
| 16-Jul-26 | Buy | David Hallas | 89.50p | 22,346 | £19,999.67 |
| Currency | UK Pounds |
| Share Price | 95.71p |
| Change Today | -1.29p |
| % Change | -1.33 % |
| 52 Week High | 114.00 |
| 52 Week Low | 73.00 |
| Volume | 48,777 |
| Shares Issued | 67.76m |
| Market Cap | £64.85m |
| Beta | 0.01 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Latest | Previous | |
|---|---|---|
| Final | Final | |
| Ex-Div | 23-Sep-21 | 26-Sep-19 |
| Paid | 22-Oct-21 | 16-Oct-19 |
| Amount | 1.00p | 7.04p |
| Time | Volume / Share Price |
| 14:43 | 1,018 @ 98.20p |
| 14:34 | 441 @ 98.20p |
| 14:08 | 2,350 @ 98.30p |
| 14:08 | 1,729 @ 96.15p |
| 13:22 | 184 @ 98.30p |
| CFO | Christopher Wilks |
| CEO | David Hallas |
You are here: research